The team, led by corresponding author JinFang Zhang of the hospital’s Department of Pediatric Hematology, enrolled 152 pediatric patients diagnosed and treated at the institution between 2019 and 2023. Every child underwent comprehensive subtyping using the so-called MICM framework, which combines morphology, immunology, cytology, and molecular biology to classify leukemia as precisely as possible. Of the cohort, 129 children, or 84.9 percent, had the common B-cell form of the disease, while 23 children, or 15.1 percent, had the rarer T-cell variant. Twenty-five patients, representing 16.4 percent of the group, were classified as having refractory disease, meaning their leukemia did not respond adequately to initial therapy.

To search for genetic factors underlying treatment failure, the researchers extracted DNA from bone marrow samples obtained either at initial diagnosis or during disease progression and subjected it to whole exome sequencing. This technique captures the protein-coding regions of the genome, where many disease-relevant mutations reside. The sequencing revealed that 32 of the 152 children, or 21.0 percent, carried mutations in the TTN gene. Strikingly, eight of these TTN-mutated patients had relapsed or refractory disease, a proportion that immediately caught the investigators’ attention given the gene’s previously unexplored role in leukemia biology.

Titin is a biological giant. Spanning more than 30,000 amino acids, it is the largest single protein encoded by the human genome, and its gene occupies one of the largest loci in human DNA. In muscle cells, titin acts as a molecular spring, anchoring thick filaments to the Z-disc of the sarcomere and providing passive elasticity that allows the heart to refill and skeletal muscle to recoil. Mutations in TTN have long been studied in cardiology, where truncating variants are a leading cause of inherited dilated cardiomyopathy. Its appearance in a hematologic malignancy highlights a growing recognition that structural and scaffolding proteins can influence cell behavior far beyond their classical anatomical roles, potentially affecting nuclear mechanics, signaling, and gene regulation in dividing cells.

The clinical correlations in the new study were consistent and statistically meaningful. Children with TTN mutations showed a prednisone resistance rate of 34.4 percent, roughly double the 17.5 percent observed in children without the mutations. Prednisone, a glucocorticoid, is a cornerstone of ALL induction therapy, and in vivo response to a seven-day prednisone prephase is one of the most powerful early predictors of outcome in pediatric protocols. Resistance to this drug at the start of treatment signals that leukemic blasts are less susceptible to one of the most effective agents in the regimen, and it has historically been linked to higher relapse risk.

Minimal residual disease measurements reinforced the picture. MRD refers to the small number of leukemic cells that persist in the bone marrow after treatment and can only be detected with highly sensitive tools such as flow cytometry or molecular assays. In the TTN-mutated group, 34.3 percent of children had MRD levels above 10 percent on day 15 of induction, compared with 15.8 percent of the TTN-negative group. By day 33, the threshold for an adequate response tightens dramatically, and 25.0 percent of TTN-mutated children still had MRD above 0.1 percent, versus 10.0 percent of those without mutations. Multivariate logistic regression analysis, which adjusts for confounding variables, confirmed that the TTN-mutated group experienced significantly greater prednisone resistance and suboptimal MRD response during induction therapy, with p values below 0.05.

Survival analysis added a temporal dimension to these findings. When the investigators examined progression-free survival, they found that children carrying TTN mutations had a significantly higher incidence of early disease recurrence. Early relapse, occurring during or shortly after frontline therapy, is among the most ominous events in pediatric ALL, because it often indicates a biologically aggressive leukemia that has already demonstrated the ability to survive intensive chemotherapy. Interestingly, however, the study found no correlation between TTN mutation status and overall recurrence across the full follow-up period, suggesting that the gene’s influence may be concentrated in the earliest and most vulnerable phase of treatment rather than defining long-term relapse risk across the board.

The authors describe their results as the first evidence linking TTN mutation to refractory ALL, and that novelty is both the study’s strength and its limitation. Because titin’s coding sequence is so vast, it accumulates a high background rate of mutations in many cancers, and disentangling true driver mutations from passenger events requires careful functional work that observational sequencing alone cannot provide. The precise mechanism by which TTN alterations might confer glucocorticoid resistance in lymphoblasts remains unknown. Possible avenues include effects on cell mechanics and apoptosis, altered nuclear architecture, or interactions with known glucocorticoid resistance pathways, but these hypotheses will need to be tested in laboratory models before the association can be translated into biology.

Even so, the clinical implications are worth taking seriously. If TTN mutation status can be confirmed as a marker of poor early response in larger, independent cohorts, it could eventually be incorporated into risk stratification at diagnosis, allowing oncologists to identify children who might benefit from intensified therapy, alternative agents, or closer MRD monitoring from the outset. Whole exome sequencing is already becoming routine in many pediatric oncology centers, so adding TTN to the interpretive panel would be technically straightforward. The study also provides a reference point for designing new strategies against drug resistance, a goal that remains central to improving outcomes for the small but medically significant fraction of children whose leukemia defies current protocols.

The research, conducted at Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, and Southern Medical University in Guangzhou, was approved by the hospital’s ethics committee and carried out with informed consent from parents and legal guardians. The work was published open access, with the authors reporting no competing interests and no external funding sources. For families affected by childhood leukemia, the study does not change treatment today, but it adds a new name to the growing list of genes that shape how this disease behaves. For researchers, it opens an intriguing question about how the body’s largest protein, famous for keeping hearts beating and muscles springing, may also help determine whether a child’s leukemia surrenders to chemotherapy or fights back.

Subject of Research: Association of titin gene mutations with refractory pediatric acute lymphoblastic leukemia

Article Title: Titin gene mutation is related to refractory acute lymphoblastic leukemia in children

Article References: Zhang, J., Zeng, L., Wang, Y., Zhong, M., Feng, B., Yang, Q., & Li, X. (2026). Titin gene mutation is related to refractory acute lymphoblastic leukemia in children. BMC Cancer. https://doi.org/10.1186/s12885-026-17113-9

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17113-9

Keywords: titin, TTN gene mutation, acute lymphoblastic leukemia, pediatric oncology, drug resistance, prednisone resistance, minimal residual disease, whole exome sequencing, relapse, BMC Cancer, genetics, hematology

The distinction between active relaxation and passive stiffness is central to understanding why the review’s cautious conclusion matters. Active relaxation is an energy-consuming process: after each heartbeat, calcium must be pumped back into the sarcoplasmic reticulum by SERCA2a, the sarco/endoplasmic reticulum calcium ATPase, and any residual calcium bound to the contractile proteins must be released so that cross-bridges detach and force declines. If calcium removal slows or myofilaments remain activated longer than they should, the ventricle begins to fill while it is still generating tension, and filling pressures rise. Passive stiffness, by contrast, is a property of the relaxed cell itself, determined largely by titin, the giant spring-like protein that spans from the Z-disc to the M-band of the sarcomere. Titin’s stiffness can be tuned by isoform switching, with the more compliant N2BA isoform giving way to the stiffer N2B isoform in some settings, and by phosphorylation of its elastic PEVK and N2B segments through kinases such as protein kinase A and protein kinase G. Hypophosphorylation of titin, oxidative modifications, and shifts in isoform ratio have all been proposed as mechanisms contributing to the elevated diastolic stiffness characteristic of HFpEF.

What makes the review’s framework particularly useful is its insistence on formal statistical testing of sex as a modifier. In experimental biology, it is common to report that females and males differ in some measured quantity, but a simple difference in a single endpoint does not establish that sex modifies the disease process. A true modifier effect requires a statistically significant interaction term, either sex by disease or sex by target, demonstrating that the effect of disease, or the response to an intervention, is itself different between the sexes. This is a much higher bar than demonstrating a baseline difference, and it is the appropriate standard when the clinical question is whether men and women should be classified or treated differently. By applying this standard systematically across the literature on calcium handling, myofilament function, titin, and mitochondrial bioenergetics, the authors converted a sprawling and often contradictory body of work into a much smaller set of defensible claims.

The result is striking in its sparseness. Among all the studies surveyed, the late sodium current emerged as the only active-relaxation-related cellular endpoint with a reported formal sex by disease interaction. The late sodium current is a small, sustained inward flow of sodium ions during the plateau phase of the cardiac action potential, and its pathological augmentation in disease states is thought to drive sodium and calcium overload through the sodium-calcium exchanger, contributing to diastolic tension and arrhythmogenic risk. The drug ranolazine, which suppresses the late current, has been tested clinically in the RALI-DHF trial for diastolic heart failure, making this target one of the few with a direct translational thread running from cellular electrophysiology to human intervention. Yet even here, the review notes that the reported sex interaction was electrophysiological rather than mechanical: the difference appeared in ionic current measurements, not in a demonstrated difference in how relaxation or stiffness responded. Without that mechanical link, the interaction remains an observation about membrane physiology rather than a guide to therapy.

The titin story illustrates a different kind of evidentiary gap. There is little doubt that titin modifications can change diastolic properties; interventions that alter titin phosphorylation or isoform expression have modified passive stiffness and filling in several HFpEF-like animal models, including models combining hypertension and metabolic stress such as the ZSF1 hybrid rat and models using L-NAME to induce nitric oxide synthase inhibition. Protein kinase G signaling, which phosphorylates titin and reduces its stiffness, has been a particularly attractive mechanistic target because it connects nitric oxide biology, cGMP signaling, and the phosphodiesterase pathways that have been explored pharmacologically in HFpEF. But the review’s systematic search found no experiment in which an independent laboratory replicated a sex-modified mechanical response to a titin-directed intervention. In other words, titin is clearly modifiable, and titin stiffness is clearly relevant to HFpEF, but the claim that women’s titin behaves differently from men’s titin in disease, in a way that would justify sex-specific treatment, has not been demonstrated under conditions that meet modern standards of rigor.

Mitochondrial bioenergetics and redox state occupy the connective position in this framework, and the review treats them accordingly. The energetic cost of relaxation is substantial: SERCA2a consumes a large fraction of the ATP generated by the cardiomyocyte, and any impairment of oxidative phosphorylation, NAD+ availability, or mitochondrial quality control can slow calcium reuptake and prolong contraction. Oxidative stress adds a second layer of vulnerability, because reactive oxygen species can modify ryanodine receptors, promote calcium leak, stiffen titin through oxidative cross-linking, and alter myofilament protein function. Pathways such as sirtuin 3, which depends on NAD+ and regulates mitochondrial protein acetylation, and calcium/calmodulin-dependent protein kinase II, which links calcium handling to oxidative stress, have each been implicated in diastolic dysfunction in experimental models. Interventions aimed at restoring NAD+ pools or reducing oxidative damage have improved diastolic phenotypes in some HFpEF-like settings. Yet here again, the review found no replicated demonstration that these bioenergetic interventions produce different mechanical benefits in females versus males, despite the plausible biological reasons to expect such differences, including known sex differences in mitochondrial function, estrogen-dependent regulation of energetics, and redox enzyme expression.

The confounding landscape surrounding this literature is unusually dense, and the review is careful to enumerate it. Findings varied with the animal model employed, the genetic strain, the age of the animals, their reproductive state, the specific disease driver used to induce the HFpEF phenotype, the stage of disease at which measurements were made, and the assay used to assess function. Each of these variables can plausibly interact with sex. Reproductive state is especially important in females, since estrogen status influences calcium handling proteins, mitochondrial enzymes, and titin phosphorylation, and ovariectomy versus intact status can change experimental outcomes. Age interacts with both sex and disease, because HFpEF is predominantly a disease of older adults and many animal models study young animals. Disease drivers matter because hypertension-driven, metabolic-driven, and anemia-driven HFpEF models produce overlapping but distinct cellular phenotypes. A sex difference observed in one combination of these variables may simply not generalize to another, which is precisely the pattern the review documents.

Human evidence, which would ideally anchor the field, is itself fragmented. Studies of ventricular tissue from patients with HFpEF have documented slowed active relaxation, elevated passive stiffness, and metabolic remodeling, including shifts in substrate utilization and mitochondrial protein expression. But these findings come from separate cohorts, often with small sample sizes, and the role of sex within each finding remains unresolved. Human myocardial tissue is difficult to obtain, typically available only from surgical procedures such as valve replacement or from transplant and autopsy material, and the underlying disease etiologies of donors vary widely. Direct comparisons of women and men using the same cellular assays on matched tissue are rare. This means that even the well-documented cellular abnormalities of HFpEF cannot currently be assigned a sex-specific prevalence or magnitude with confidence.

The review also draws a useful methodological distinction among the kinds of comparisons that would actually advance the field. One question is whether disease affects females and males differently, which requires comparing each sex against its own healthy control. A second question is whether a molecular target functions differently within diseased hearts of each sex, which requires testing the target’s contribution in both sexes under disease conditions. A third question is whether any observed difference is specific to disease rather than a baseline sex difference that exists independently of pathology. Many published studies conflate these questions, reporting sex differences without the appropriate controls to determine what kind of difference has been found. Prespecifying sex comparisons and linking them to a relevant functional endpoint, such as relaxation kinetics or passive force, would allow future studies to distinguish genuine modifier effects from incidental observations.

The clinical implications of this cautious conclusion deserve emphasis. If sex alone cannot define calcium-dominant or titin-dominant HFpEF endotypes, then treatment selection based on a patient’s sex would currently lack a mechanistic foundation. This does not mean sex is irrelevant to HFpEF; the epidemiological preponderance of women, differences in ventricular remodeling patterns, and known hormonal influences on cardiovascular physiology all remain real and clinically important. It means instead that the cellular mechanisms underlying any sex-related clinical differences have not been pinned down with the specificity needed to guide endotyping. The practical path forward suggested by the review is to treat sex as a hypothesis-generating variable to be tested in defined experimental and clinical settings, rather than as a classification tool. Until replicated, sex-stratified, mechanically anchored evidence accumulates, the heterogeneous reality of HFpEF, in which multiple cellular defects coexist and vary with context, remains the best available description of the disease for both women and men.

Subject of Research: Sex differences in cardiomyocyte relaxation mechanisms in heart failure with preserved ejection fraction

Article Title: Evaluating sex as a modifier of cardiomyocyte relaxation in heart failure with preserved ejection fraction: calcium handling, titin, and bioenergetics

Article References: Wang, B., & Dai, X.-C. (2026). Evaluating sex as a modifier of cardiomyocyte relaxation in heart failure with preserved ejection fraction: calcium handling, titin, and bioenergetics. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00993-8

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00993-8

Keywords: HFpEF, cardiomyocyte relaxation, calcium handling, titin, passive stiffness, mitochondrial bioenergetics, sex differences, late sodium current, NAD+, diastolic dysfunction, heart failure, Biology of Sex Differences